CYP19A1 and breast cancer: Based on our observations, early maintenance therapy with aromatase inhibitors is recommended for this subgroup of patients, which is also supported by previous studies demonstrating a therapeutic effect of receptor distribution and expression levels in patients with metastatic estrogen and progesterone receptor positive breast cancers [38,39].